Clinical trials: Pulmonary Hypertension, Primary, 2
Pulmonary Hypertension
ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)
The primary objective is to determine the effect of ambrisentan on exercise capacity in subjects with PAH.
- Trial name
- NCT00091598
- Testing
- Ambrisentan
- Where
- 46 sites in United States, Australia and 1 more
- Volunteers
- 372 people
- Sponsor
- Gilead Sciences
PAH
CXA-10 Study in Subjects With Pulmonary Arterial Hypertension
This is a Phase 2, multicenter, open-label extension (OLE) of study CXA-10-301, to evaluate the long term safety and efficacy of daily dosing of CXA-10.
- Trial name
- NCT04053543
- Testing
- CXA-10
- Where
- 37 sites in United States, United Kingdom
- Volunteers
- 33 people
- Sponsor
- Complexa, Inc.
Pulmonary Hypertension
Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.
Pulmonary Arterial Hypertension (PAH) is a severe progressive disease with a high mortality. Although several drugs are available for the treatment of PAH none offer a cure, therefore there is still a high medical need for new…
- Trial name
- PATENT PLUS (NCT01179334)
- Testing
- Riociguat (Adempas, BAY63-2521), Sildenafil
- Where
- 25 sites in United States, Austria and 7 more
- Volunteers
- 18 people
- Sponsor
- Bayer
Pulmonary Hypertension
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH.
- Trial name
- NCT07073820
- Testing
- PF-07868489
- Where
- 27 sites in United States, Australia and 8 more
- Volunteers
- 42 people
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)
This is a randomized, double-blind, multi-center, placebo-controlled dose-ranging clinical trial of two IkT-001Pro doses in patients with PAH designed to assess safety, tolerability and efficacy.
- Trial name
- NCT06643143
- Testing
- IkT-001Pro
- Sponsor
- Inhibikase Therapeutics
Pulmonary Arterial Hypertension (PAH)
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH).
- Trial name
- ILLUMINATE (NCT07318597)
- Testing
- REGN13335
- Where
- 33 sites in United States, Australia and 8 more
- Volunteers
- 99 people
- Sponsor
- Regeneron Pharmaceuticals
Pulmonary Arterial Hypertension
Fluoxetine in Pulmonary Arterial Hypertension (PAH) Trial
This protocol describes an open-label phase 2 clinical trial of fluoxetine in PAH looking at change in pulmonary vascular resistance (PVR) as the primary endpoint.
- Trial name
- PAH (NCT03638908)
- Testing
- Fluoxetine
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Noncommunicable Diseases, Hypertension
Integrated NCD Intervention in Rural Nepal
We will test an NCD intervention bundle incorporating the World Health Organisation (WHO)'s Package for Essential Non-Communicable Disease Interventions (PEN) within an approximate population of 300,000 people in rural Nepal.
- Conditions
- Noncommunicable Diseases, Hypertension, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, Type 2
- Trial name
- NCT04087369
- Testing
- Bundled NCD WHO PEN Intervention
- Where
- 2 sites in Nepal
- Sponsor
- Possible
Pulmonary Artery Hypertension
A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension
Pulmonary hypertension Group 2 (PH 2) associated with left-sided heart disease is relatively common, is associated with a poor prognosis, and unfortunately there are no proven medical treatments beyond attempts at correcting the…
- Trial name
- NCT02684786
- Testing
- reserpine, stellate ganglion block, lidocaine
- Where
- United States
- Sponsor
- Mayo Clinic
Pulmonary Arterial Hypertension
Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study
The main OBJECTIVE of this proposal is to extend the investigator's preclinical findings on the role of epigenetics and DNA damage and Bromodomain-Containing Protein 4 (BRD4) inhibition as a therapy for a devastating disease…
- Trial name
- APPRoAcH-p (NCT03655704)
- Testing
- Apabetalone
- Where
- 2 sites in Canada
- Volunteers
- 7 people
- Sponsor
- Steeve Provencher
Pulmonary Arterial Hypertension
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
The purpose of this study is to evaluate the safety and effectiveness of an investigational/experimental drug called AIR001. To test the effectiveness, the study will evaluate how AIR001 affects the blood vessels in the lungs and…
- Trial name
- NCT01725256
- Testing
- AIR001 (sodium nitrite inhalation solution)
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 29 people
- Sponsor
- Aires Pharmaceuticals, Inc.
Pulmonary Arterial Hypertension
Apabetalone for Pulmonary Arterial Hypertension
Throughout the past twenty years, numerous specific pharmacologic agents targeting the endothelial dysfunction associated with PAH have emerged.
- Trial name
- APPROACH-2 (NCT04915300)
- Testing
- Apabetalone
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- Laval University
Pulmonary Arterial Hypertension
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to <18 years of age with PAH World Health Organization (WHO)…
- Trial name
- MOONBEAM (NCT05587712)
- Testing
- Sotatercept
- Where
- 35 sites in United States, Australia and 10 more
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension, Hypertension, Pulmonary
A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)
This is a two-part (Phase 2/Phase 3) study of frespaciguat, an inhaled soluble guanylate cyclase stimulator, in participants with pulmonary arterial hypertension (PAH).
- Trial name
- NCT04732221
- Testing
- Frespaciguat
- Where
- 91 sites in United States, Argentina and 16 more
- Volunteers
- 168 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults
Phase 1b/2 Study of HS235 Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Activin Signaling Inhibitor HS235 Added to Background Treatment in Adults with Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT07143448
- Testing
- HS235
- Where
- 7 sites in United States, Spain and 1 more
- Volunteers
- 90 people
- Sponsor
- 35Pharma Inc., a GSK company
Pulmonary Arterial Hypertension
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
This Phase 2, randomized, double-blind, placebo-controlled, multicenter, dose-ranging study will compare the efficacy, safety, and tolerability of cicletanine hydrochloride (HCl) to placebo in subjects with PAH.
- Trial name
- NCT00832507
- Testing
- Cicletanine
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 162 people
- Sponsor
- Gilead Sciences
Arterial Hypertension, Pulmonary
A Study of Macitentan in Children Below 2 Years of Age
The purpose of this study is to learn what happens to macitentan and its active metabolite (aprocitentan) in the body of children aged between 1 month and 2 years.
- Trial name
- NCT05731492
- Testing
- Macitentan
- Where
- 4 sites in Germany, Poland
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
The purpose of the study is to learn how the study medicine called PF-07868489 is tolerated and acts in healthy adult people and people with pulmonary arterial hypertension (PAH).
- Trial name
- NCT06137742
- Testing
- PF-07868489
- Where
- 46 sites in United States, Australia and 10 more
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension
Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
Phase 3, placebo controlled, double-blind, randomized clinical study to determine safety, tolerability, and efficacy of pulsed, inhaled nitric oxide (iNO) versus placebo in symptomatic subjects with pulmonary arterial…
- Trial name
- INOvation-1 (NCT02725372)
- Testing
- Inhaled Nitric Oxide 75 mcg/kg IBW/hr
- Where
- 109 sites in United States, Australia and 16 more
- Volunteers
- 207 people
- Sponsor
- Bellerophon Pulse Technologies
Chronic Right-Sided Heart Failure, Pulmonary Arterial Hypertension
Spironolactone Therapy in Chronic Stable Right HF Trial
The purpose of this study is to evaluate the safety, tolerability and mechanistic effects of spironolactone, an aldosterone receptor antagonist, on sympathetic nervous system activity and right heart function and remodeling in…
- Conditions
- Chronic Right-Sided Heart Failure, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Primary, 2, Pulmonary Hypertension, Primary, 3
- Trial name
- STAR-HF (NCT03344159)
- Testing
- Spironolactone, PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82, Cardiac MRI (Gadolinium enhanced)
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Ottawa Heart Institute Research Corporation